浙江大學教授，博士生導師；
基本介紹
- 中文名：朱峰
- 國籍：中國
- 民族：漢
- 職業：教授
- 畢業院校：新加坡國立大學、北京師範大學
- 研究領域：藥物設計，藥靶發現
人物經歷,研究興趣,代表性論文,
人物經歷
2017年07月至今：浙江大學 藥學院 教授，博士生導師
2016年06月至今：中國計算機學會 生物信息學專業組 委員
2016年02月至今：中國藥理學會 精準分析藥理學專業委員會（籌） 委員
2014年09月至今：中國化學會 計算機化學專業委員會 委員
2014年02月至2017年06月：重慶大學 藥學院 教授，博士生導師
2012年07月至2014年02月：重慶大學 創新藥物研究中心 研究員，博士生導師
2012年01月至2012年07月：新加坡國立大學 藥學系 Research Fellow
2011年01月至2011年12月：新加坡國立大學 藥學系 Research Associate
2010年07月至2011年01月：新加坡國立大學 亞洲研究中心和藥學系 Research Assistant
研究興趣
運用人工智慧（機器學習、深度學習）、複雜網路分析等生物信息學手段和組學（蛋白組、代謝組）新技術，分析和發現具有治療效用藥物靶點的成藥性和系統生物學特性，發展新穎的用於新藥靶發現的預測方法和線上工具，並進一步研究藥物與重要靶點的相互作用機制。
代表性論文
Y. H. Li, C. Y. Yu, X. X. Li, P. Zhang, J. Tang, Q. X. Yang, T. T. Fu, X. Y. Zhang, X. J. Cui, G. Tu, F. Y. Yang, C. Qin, X. Zeng, Z. Chen, Y. Z. Chen*, F. Zhu*. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res. 46(D1): 1121-1127 (2018).
F. Zhu*, X. X. Li, S. Y. Yang, Y. Z. Chen*. Clinical success of drug targets prospectively predicted by in-silico study. Trends Pharmacol Sci. 39(3): 229-231 (2018).
F. Y. Yang, G. X. Zheng, T. T. Fu, X. F. Li, G. Tu, Y. H. Li, X. J. Yao, W. W. Xue*, F. Zhu*. Prediction of binding mode and resistance profile for dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase associated ribonuclease H. Phys Chem Chem Phys. doi: 10.1039/C8CP01843J (2018).
Z. J. Han, W. W. Xue, L. Tao,F. Zhu*. Identification of novel immune-relevant drug target genes for alzheimer's disease by combining ontology inference with network analysis. CNS Neurosci Ther. CNSNT-2018-279 (2018).
J. B. Fu, J. Tang, Y. X. Wang, X. J. Cui, Q. X. Yang, J. J. Hong, X. X. Li, S. Li, Y. Z. Chen, W. W. Xue,F. Zhu*. Discovery of the consistently well-performed analysis chain for SWATH-MS based pharmacoproteomic quantification.Front Pharmacol. 9: 681 (2018).
T. T. Fu, G. X. Zheng, G. Tu, F. Y. Yang, Y. Z. Chen, X. J. Yao, X. F. Li, W. W. Xue*, F. Zhu*. Exploring the binding mechanism of metabotropic glutamate receptor 5 negative allosteric modulators in clinical trials by molecular dynamics simulations. ACS Chem Neurosci. 9(6): 1492-1502 (2018).
W. W. Xue, P. P. Wang, G. Tu, F. Y. Yang, G. X. Zheng, X. F. Li, X. X. Li, Y. Z. Chen, X. J. Yao, F. Zhu*. Computational identification of the binding mechanism of triple reputake inhibitor amitifadine for the treatment of major depressive disorder. Phys Chem Chem Phys. 20(9): 6606-6616 (2018).
W. W. Xue, F. Y. Yang, P. P. Wang, G. X. Zheng, Y. Z. Chen, X. J. Yao, F. Zhu*. What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation. ACS Chem Neurosci. 9(5): 1128-1140 (2018).
C. Y. Yu, X. X. Li, H. Yang, Y. H. Li, W. W. Xue, Y. Z. Chen, L. Tao, F. Zhu*. Assessing the performances of protein function prediction algorithms from the perspectives of identification accuracy and false discovery rate. Int J Mol Sci. 19(1): 183 (2018).
B. Li, J. Tang, Q. X. Yang, S. Li, X. J. Cui, Y. H. Li, Y. Z. Chen, W. W. Xue, X. F. Li, F. Zhu*. NOREVA: normalization and evaluation of MS-based metabolomics data. Nucleic Acids Res. 45(W1): 162-170 (2017).
P. P. Wang, X. Y. Zhang, T. T. Fu, S. Li, B. Li, W. W. Xue*, X. J. Yao, Y. Z. Chen, F. Zhu*. Differentiating physicochemical properties between addictive and nonaddictive ADHD drugs revealed by molecular dynamics simulation studies. ACS Chem Neurosci. 8(6): 1416-1428 (2017).
G. X. Zheng, W. W. Xue*, F. Y. Yang, Y. Zhang, Y. Z. Chen, X. J. Yao, F. Zhu*. Revealing vilazodone's binding mechanism underlying its partial agonism to 5-HT1A receptor in the treatment of major depressive disorder. Phys Chem Chem Phys. 19(42): 28885-28896 (2017).
P. P. Wang, T. T. Fu, X. Y. Zhang, F. Y. Yang, G. X. Zheng, W. W. Xue*, Y. Z. Chen, X. J. Yao, F. Zhu*. Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD. BBA Gen Subjects. 1861(11A): 2766-2777 (2017).
F. Y. Yang, T. T. Fu, X. Y. Zhang, J. Hu*, W. W. Xue*, G. X. Zheng, B. Li, Y. H. Li, X. J. Yao, F. Zhu*. Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters. Mol Simul. 43(13-16): 1089-1098 (2017).
H. Yang, C. Qin, Y. H. Li, L. Tao, J. Zhou, C. Y. Yu, F. Xu, Z. Chen, F. Zhu*, Y. Z. Chen*. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res. 44(D1): 1069-1074 (2016).
B. Li, J. Tang, Q. X. Yang, X. J. Cui, S. Li, S. J. Chen, Q. X. Cao, W. W. Xue, N. Chen, F. Zhu*. Performance evaluation and online realization of data-driven normalization methods used in LC/MS based untargeted metabolomics analysis. Sci Rep. 6: 38881 (2016).
W. W. Xue, P. P. Wang, B. Li, Y. H. Li, X. F. Xu, F. Y. Yang, X. J. Yao, Y. Z. Chen, F. Xu*, F. Zhu*. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. Phys Chem Chem Phys. 18(4): 3260-3271 (2016).
G. X. Zheng, W. W. Xue*, P. P. Wang, F. Y. Yang, B. Li, X. F. Li, Y. H. Li, X. J. Yao, F. Zhu*. Exploring the inhibitory mechanism of approved selective norepinephrine reuptake inhibitors and reboxetine enantiomers by molecular dynamics study. Sci Rep. 6: 26883 (2016).
L. Tao, F. Zhu, F. Xu, Z. Chen, Y. Y. Jiang*, Y. Z. Chen*. Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. Pharmacol Res. 102: 123-131 (2015).
P. P. Wang, F. Y. Yang, H. Yang, X. F. Xu, D. Liu, W. W. Xue, F. Zhu*. Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. Biomed Mater Eng. 26(S1): 2233-2239 (2015).
L. Tao, F. Zhu, C. Qin, C. Zhang, F. Xu, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. The nature's contribution to today's pharmacopeia. Nat Biotechnol. 32(10): 979-980 (2014).
F. Zhu, Z. Shi, C. Qin, L. Tao, X. Liu, F. Xu, L. Zhang, Y. Song, X. H. Liu, J. X. Zhang, B. C. Han, P. Zhang, Y. Z. Chen*. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40(D1): 1128-1136 (2012).
F. Zhu, C. Qin, L. Tao, X. Liu, Z. Shi, X. H. Ma, J. Jia, Y. Tan, C. Cui, J. S. Lin, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci U S A. 108(31): 12943-12948 (2011).
H. B. Rao, F. Zhu, G. B. Yang, Z. R. Li*, Y. Z. Chen. Update of PROFEAT: a web server for computing structural and physicochemical features of proteins and peptides from amino acid sequences. Nucleic Acids Res. 39(W1): 385-390 (2011).
F. Zhu, B. C. Han, P. Kumar, X. H. Liu, X. H. Ma, X. N. Wei, L. Huang, Y. F. Guo, L. Y. Han, C. J. Zheng, Y. Z. Chen*. Update of TTD: therapeutic target database. Nucleic Acids Res. 38(D1): 787-791 (2010).
F. Zhu, L. Y. Han, C. J. Zheng, B. Xie, M. T. Tammi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical and system profile of successful targets. J Pharmacol Exp Ther. 330(1): 304-315 (2009).
J. Jia, F. Zhu, X. H. Ma, Z. W. Cao, Y. X. Li, Y. Z. Chen*. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 8(2): 111-128 (2009).
F. Zhu, L. Y. Han, X. Chen, H. H. Lin, S. Ong, B. Xie, H. L. Zhang, Y. Z. Chen*. Homology-free prediction of functional class of proteins and peptides by support vector machines. Curr Protein Pept Sci. 9(1): 70-95 (2008).
